THE 30-SECOND OVERVIEW
GHK-Cu dosage research quick start
GHK-Cu has one of the deeper research records among copper peptides, but its dosing literature is harder to summarise than most, because the studied quantities differ by orders of magnitude depending on route. A topical concentration and an injectable quantity are not comparable figures, and much of the confusion around GHK-Cu protocols comes from treating them as if they were.
Check the formulation
GHK-Cu 50 mg vial. Other formats and blends may have different strengths.
Amount ≠ schedule
Concentration arithmetic does not determine dosing frequency or a safe human daily amount.
LABORATORY CONCENTRATION MATH
GHK-Cu dosage calculator
Calculate the amount in a laboratory sample of the 50 mg GHK-Cu vial. Enter the final solution volume, not the container capacity.
Enter positive volumes; the sample cannot exceed the final solution volume.
Illustrative arithmetic only. These inputs are not recommended preparation volumes or doses. This calculator does not recommend a route or schedule for human use.
Why GHK-Cu Dosing Splits by Route
GHK-Cu is a tripeptide, glycyl-L-histidyl-L-lysine, complexed with a copper ion. Both halves matter to how it is studied.
The peptide portion determines receptor and matrix interactions. The copper portion carries its own constraints: copper is an essential trace element at low quantities and a pro-oxidant at higher ones, so studies involving systemic exposure are bounded by copper load in a way that purely peptide-based compounds are not.
This is why the literature does not offer a single figure. Topical research reports concentrations, because what matters is what reaches the skin. Injectable research reports quantities, because what matters is systemic exposure and total copper delivered. Converting between them is not straightforward and the literature generally does not attempt it. Route also changes delivery for nasal and sublingual preparations, which the dosing literature treats separately again.
Topical Research Concentrations
The largest body of GHK-Cu work is dermatological and topical, and it clusters in a fairly consistent band.
Published cosmetic and dermatological studies typically evaluate GHK-Cu in aqueous or hydroalcoholic vehicles at roughly 0.1% to 2% by weight. Formulation work in the cosmetic chemistry literature generally sits at the lower end of that range, with concentrations around 0.1% to 0.5% common in products evaluated for skin outcomes.
Higher is not straightforwardly better in this literature. Copper peptide formulations face a stability constraint: copper can oxidise or exchange in certain vehicles, and higher concentrations tend to compound formulation problems rather than proportionally increase delivered activity. Studies examining vehicle effects report that pH range, chelator presence, and the base itself materially change how much intact complex survives and penetrates.
Vehicle choice is not a secondary detail. The same nominal concentration in different bases can produce substantially different delivery, which is a recurring source of non-comparability across topical studies.
Injectable and Systemic Research
Injectable GHK-Cu research is far sparser, and quantities are much smaller than the topical figures might suggest.
Animal studies investigating systemic administration have used quantities in the low milligram-per-kilogram range and below, with wound and tissue-repair models generally reporting single-digit milligram quantities per animal rather than the concentrations seen in topical work. The relevant constraint is copper load: because each GHK molecule carries a copper ion, total copper scales directly with peptide quantity, and this bounds systemic protocols independently of the peptide's own activity.
Human injectable data is limited. The bulk of GHK-Cu's human evidence is topical or ex vivo, and researchers working with injectable preparations are extrapolating from preclinical models rather than following an established human protocol.
Reconstitution and Handling
GHK-Cu is supplied lyophilised, typically as a blue or blue-green powder. The colour comes from the copper complex and is a rough visual indicator that the complex is intact. The 50mg vial ships in that form.
Standard handling applies: reconstitute with bacteriostatic or sterile water introduced gently against the vial wall, swirl rather than shake, and store cold and dark. Copper peptides warrant more attention to light and oxidation than plain peptides, since the copper centre is the reactive part.
A colour shift away from the characteristic blue is worth noting as a signal that something has changed in the complex. It is not a precise assay, but it is the one observation available without instrumentation.
Concentration follows from diluent volume, and as with any lyophilised peptide, a protocol carried over from a vial reconstituted differently will be off by exactly the ratio of the two volumes, which a reconstitution calculator resolves in one step. With GHK-Cu this compounds, because the copper load moves with it.
GHK-Cu in Blends
GHK-Cu appears in multi-peptide research blends, where the quantity is fixed by the blend rather than chosen independently. The Stemcode Glow vial contains GHK-Cu 20mg alongside BPC-157 5mg and TB-500 5mg; the Klow vial contains GHK-Cu 50mg with BPC-157 10mg, TB-500 10mg and KPV 10mg.
The practical consequence is that GHK-Cu quantity and total copper load differ substantially between those two preparations: Klow carries 2.5 times the GHK-Cu of Glow. A protocol built around one is not transferable to the other without recalculating, which is a more common oversight than the composition difference itself. Our comparison of the two blends covers how they differ in full.
What the Research Does Not Establish
The gap between topical and systemic evidence is the most important limit. GHK-Cu's strongest data is topical and dermatological; extending conclusions from that work to injectable protocols crosses a boundary the literature does not support.
Much of the frequently cited mechanistic work, including the widely referenced finding that GHK modulates a very large number of human genes, comes from gene expression analysis rather than outcome studies. That is real evidence about mechanism and weak evidence about results.
Concentration ranges in topical studies are also not directly comparable across papers, because vehicle differences change delivery. A 1% figure from one study and a 1% figure from another may not represent equivalent exposure.
The Takeaway
GHK-Cu research divides cleanly by route. Topical studies cluster around 0.1% to 2% concentrations in aqueous or hydroalcoholic vehicles, with lower concentrations common and vehicle choice mattering as much as concentration. Injectable work uses far smaller quantities and is bounded by copper load rather than peptide activity, with most of it preclinical.
Everything we stock is listed under GHK-Cu for sale. The single most useful handling fact is that the copper is the sensitive part. Light, oxidation and vehicle chemistry act on the complex, and the characteristic blue colour is the only free indicator that it is intact.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015, 648108.
2. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987.
3. Badenhorst, T., Svirskis, D., & Wu, Z. (2016). Physicochemical characterization of native glycyl-L-histidyl-L-lysine tripeptide for wound and tissue repair. Journal of Pharmacy and Pharmacology, 68(10), 1235-1246.
